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Prosthetic graft infection is a major complica-
tion of vascular surgery, with a high amputation
and mortality rate.1,2 The treatment of this clinical
situation remains controversial. The arterial allo-
graft was the first material used in treatment of
proximal occlusion3 or aortic aneurysms.4 Late
deterioration of the grafts5 and the development of
vascular prostheses led to abandonment of allograft
replacement. Successful results after allograft
replacement in infected ascending aortas6,7 stimu-
lated the use of allografts for aortic reconstruction
in infected sites. Kieffer et al8 obtained good
results with complete excision of infected prosthet-
ic material associated with refrigerated arterial allo-
graft replacement. Nevertheless, the use of refrig-
erated allografts raises major problems; in particu-
lar, conservation time is limited to a few weeks, and
viral serologic tests for biological security are not
able to be carried out.
The use of cryopreserved allografts is well-
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Purpose: The bacterial resistance of refrigerated and cryopreserved aortic allografts in a
highly virulent infection in a dog model was studied.
Methods: The infrarenal aorta of 12 dogs was replaced with either a cryopreserved aortic
allograft (group I, n = 6) or a refrigerated aortic allograft (group II, n = 6) in infected
sites. Allografts were harvested from dogs and stored for 1 week, either by cryopreser-
vation (–140°C) or refrigerated method (4°C), in a preservation medium. At the time of
implantation, induction of infection was achieved with an infected piece of knitted
Dacron placed just beneath the allograft. The Dacron was contaminated in vitro by soak-
ing it in a solution with Staphylococcus aureus PR209. All 12 dogs received no adjunct
antibiotic or antithrombotic therapy. Four weeks after implantation, the animals were
killed to recover the grafts for bacteriological and histological analyses. Bacterial results
were expressed as colony-forming units (CFU)/cm2 of graft material.
Results: In group I, only one allograft grew bacteria at 2.16 · 106 CFU/cm2, with a
blood culture positive for S aureus. In group II, one dog died at 3 weeks from a false
septic aneurysm rupture, all the allografts were infected (P < .05) with a mean bacteri-
al count of 9.41 ± 6.8 · 104 CFU/cm2, and three blood cultures were positive for S
aureus. The patency of the grafts was analyzed at the time of recovery. Three laminar
thrombi without occlusion were present in group I; none were present in group II. A
better preserved endothelium in group I was revealed by means of histologic analysis
staining with factor VIII antibody before implantation. After 4 weeks of implantation
in the infected site, infected allografts presented polynuclear infiltrates in the media with
a high degree of inflammatory reaction, and endothelial recovery was more significant
in group I, with numerous young plump cells. 
Conclusion: This study demonstrates that cryopreserved allografts implanted in infected sites
in a dog model can produce greater bacterial resistance. (J Vasc Surg 1999;29:1090-6.)
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known,6,9 particularly in distal revascularization
when the autogenous vein is unsuitable.10,11 Few
good clinical results with cryopreserved arterial
homografts implanted in infected sites12,13 have
been reported. However, at the same time, early
rupture and cracks in cryopreserved arterial allo-
grafts, which have led to hemorrhage or the sud-
den death of the patient, have been observed.14-16
Kieffer et al,8 who used refrigerated allografts
stored at 4°C, reported only one rupture in 43
implantations of refrigerated allografts in infected
sites. 
Only a few experimental reports have described
the behavior of allografts in infected areas17-19 with
different methods of preservation. We compared
bacterial resistance between refrigerated and cryo-
preserved aortic allografts in a dog model.
MATERIAL AND METHODS
Canine aortic model. Twelve female anglo-
french dogs, weighing 20 to 25 kg, underwent
replacement of the infrarenal aorta with a cryopre-
served aortic allograft (group I, n = 6) or a refriger-
ated aortic allograft (group II, n = 6) in infected
sites. The dogs were premedicated with Valium (0.5
mg/kg body weight) and atropine (0.2 mg/kg),
then anesthetized with thiopental (5 mg/kg),
vecuronium (0.1 mg/kg), phenopyridine (0.02
mg/kg), and celomine (1 mg/kg), intubated, and
mechanically ventilated. Anesthesia was maintained
during the procedure with the administration of
thiopental (5 mg/kg/h). All dogs were treated in
accordance with the “Guide for the Care and Use of
Laboratory Animals” (National Institutes of Health
Publication No. 86-23, revised 1985).
Under aseptic conditions, the infrarenal aorta
was exposed through a midline transperitoneal inci-
sion. Before the aorta was clamped, heparin (50
IU/kg body weight) was injected intravenously. The
infrarenal aorta was transected, and a 4-cm segment
was removed for preservation. A 4-cm segment of
cryopreserved (group I) or refrigerated (group II)
allograft was inserted in a double end-to-end anas-
tomosis with 5-0 polypropylene sutures.
Induction of infection was carried out by means
of an infected piece of knitted Dacron (Meadox
Medical, Oakland, NJ), which measured 5 by 1.5 cm
and was placed just beneath the allograft. The
Dacron graft was immersed in the inoculating solu-
tion of Staphylococcus aureus PR209 for 30 minutes
at room temperature. After immersion, the Dacron
segment was rinsed with normal saline solution to
remove nonadherent microorganisms.20 The effica-
cy of this technique has been previously demonstrat-
ed by creating a retroperitoneum or inguinal
abscess.17,18,21 The abdomen was closed in layers
after covering the graft with the retroperitoneum.
No adjunct antibiotic or antithrombotic therapy was
given to the dogs. 
Four weeks after implantation, the animals were
anesthetized and killed to recover the grafts for a
quantitative bacteriologic and histologic analysis.
Fragments of liver, spleen, and lung were harvested
at the same time for bacteriologic analysis. Venous
blood samples were obtained just before the animals
were killed for blood culture.
Fig 1. Time-kill curves of Staphylococcus aureus PR209, with cryopreservation or refrigerated
medium.
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Allograft procurement and preservation.
Each dog was, at the same time, a donor of an aortic
segment and a receiver of a preserved allograft. The
abdominal aorta harvested from the dog was flushed
with heparinized saline solution and cryopreserved
(group I) or stored in a preservation medium at 4°C
(group II) for 8 days. In group I, after procurement,
the grafts were placed, for 15 hours, in a tissue cul-
ture medium containing 500 mL RPMI 1640
(Sigma, L’Isle d’Abeau Chesnes, France), Hepes
buffer (0.1 mmol/L; Sigma), cefoxitin (240 m g/mL;
Merck Sharp, Paris, France), gentamicin (50 m g/mL;
Panpharma, Fougères, France), colistin (4000
IU/mL; Bellon, Neuilly-sur-Seine, France), and van-
comycin (50 m g/mL; Lilly France, Saint Cloud,
France) at 4°C. After 15 hours, the grafts were trans-
ferred to cryopreservation storage pouches (Gambro
CGV-4.3) containing 50 mL human albumin (4%
solution; Centre National de Transfusion Sanguine,
Paris, France) and 10% dimethyl sulfoxide (1.41
mol/L). The grafts were frozen immediately accord-
ing to an electronically monitored program (Nicool
ST20) at a controlled rate of 1.5°C/min until they
reached –40°C, then at a controlled rate of 5°C/min
until they reached –150°C. The pouches were then
stored in the vapor phase of liquid nitrogen at
–150°C. All the procedures were performed by the
Centre National de Transfusion Sanguine, Bois-
Guillaume, France. At the time of implantation, the
grafts were thawed in a 37°C waterbath and rinsed in
a normal saline solution.
In group II, after procurement, the grafts were
placed in a preservation medium19 containing: 500
mL RPMI 1640 tissue culture medium (Sigma,
France), 25 mL human albumin (20% solution;
Centre National de Transfusion Sanguine), Hepes
buffer (0.1 mmol/L; Sigma), cefuroxime (1.5
mg/mL; Glaxo, Paris, France), amphotericin B (100
m g/mL; Squibb, Neuilly-sur-Seine, France), gen-
tamicin (40 m g/mL; Panpharma), and metronida-
zole (200 m g/mL; Spécia, Paris, France). The grafts
were then stored for 8 days.
Bacterial strain. S aureus PR209 was obtained
as an isolate from the wild type P209 (Institut
Pasteur, Paris, France, ref. CIP 53136). S aureus
PR209 is a rifampin-resistant mutant characterized
by a positive coagulase, positive DNase, positive
lipase, positive alpha hemolysin, and susceptibility to
all antistaphylococcal antibiotics except rifampin.
The bacteria was stored on trypticase soy agar (TSA)
containing 100 m g/mL rifampin. The inoculating
solution was prepared when required, and the strain
was plated on TSA for 18 hours. Four colonies were
then transferred to 40 mL of trypticase soy broth
with 1% dextrose and incubated for 18 hours at
37°C. The resulting bacterial suspension was then
used as the inoculating solution. The inoculum den-
sity was controlled by back plating on TSA.
Bactericidal activity. The standard time-kill
curve method22 was used to compare the bacterici-
dal concentration of each preservation solution. A
tenfold dilution of the two solutions, cryopreserved
Fig 2. Histologic appearance of an 8-day cryopreserved abdominal aorta. Cryopreservation
preserved endothelium cells better, as evidenced by factor VIII antibody staining (arrows) at
original magnification of · 100. L, Lumen; I, intima; M, media.
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Histologic examination. Before implantation
and after explantation, allograft rings of 2 mm were
removed, fixed in 10% formalin, dehydrated, and
embedded in paraffin. Paraffin sections 5 m m thick
Fig 3. Histologic appearance of an 8-day refrigerated abdominal aorta. Staining with factor VIII
antibody at original magnification of · 100 shows the absence of the endothelium cell lining.
L, Lumen; I, intima; M, media.
Fig 4. Histologic appearance of a refrigerated allograft after
4 weeks of implantation in infected sites. Hematoxylin-
eosin stain at original magnification of · 40 shows intimal
proliferation, including significant inflammatory infiltrates.
L, Lumen; I, intima; M, media.
and refrigerated medium, were made in Mueller-
Hinton broth. A broth culture with no antibiotic
was set up as a control. The inoculum was 1 mL of
2 · 107 S aureus PR209 organisms made from an
18-hour culture. All tubes were incubated in a dry
bath at 37°C. At 0, 2, 6, 24, and 48 hours, the viable
numbers of organisms were enumerated by serial
tenfold dilutions, and 1 mL aliquots was plated on
Mueller-Hinton agar. 
Inoculum size. Before each implantation of infect-
ed Dacron, inoculum size was determined by tenfold
dilutions that were cultured onto TSA-containing
rifampin 100 mg/L and incubated for 48 hours at
37°C. Colony counts were expressed as the number of
colony forming units (CFU) per mL of inoculum.
Bacteriologic studies. Allografts were harvested
4 weeks after implantation. After dissection, an allo-
graft segment of approximately 3 cm was removed.
Length and diameter of each fragment were mea-
sured, and each fragment underwent a bacterial
count. Each graft fragment was then mechanically
crushed for 2 minutes after the addition of 2 mL
normal saline solution. The crushing effluent was
submitted to tenfold dilutions, and 0.1 mL aliquots
were subcultured onto TSA-containing rifampin
100 mg/L and incubated for 48 hours at 37°C.
Colony counts were expressed as the number of
CFU per cm2 of graft material.
Blood samples, explanted Dacron, and organ
fragments were cultured onto TSA-containing
rifampin 100 mg/L and incubated for 48 hours at
37°C. Culture results were considered positive if the
study strain of S aureus was recovered.
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were cut and stained with hematoxylin-eosin for
analysis by means of light microscopy. 
Immunoperoxydase staining. Endothelial cells
were identified by means of the immunoperoxydase
technique with human antiendothelial antifactor
VIII antibody (Dako A082, Trappes, France).
Statistical analysis. The data from these experi-
ments were analyzed with the Mann-Whitney test or
with chi-square analysis. Statistical significance was
assigned when P was less than .05. Data are present-
ed as mean ± SE.
RESULTS
Bactericidal activity. Fig 1 shows the results
of the time-kill curve studies. There was no signif-
icant difference of bactericidal activity between
cryopreserved and refrigerated medium after 6
hours.
Inoculum size. The mean inoculum size was 6 ±
0.5 · 108 CFU/mL in group I and 5.3 ± 0.7 · 108
CFU/mL in group II, with no significant difference
between the two groups. All the infected pieces of
Dacron had grown bacteria at the time of explanta-
tion. All preservation mediums were sterile.
Bacterial count. In group I (cryopreserved allo-
grafts), only one allograft grew bacteria at 2.16 ·
106 CFU/cm2, with positive blood culture and tis-
sue specimens. In group II (refrigerated allografts),
one dog died at 3 weeks from a false septic aneurysm
rupture, all the allografts were infected with a mean
bacterial count of 9.41 ± 6.8 · 104 CFU/cm2, and
3 blood cultures and tissue specimens were positive.
Graft patency. The patency of the graft was ana-
lyzed at the time of recovery. Three laminar throm-
bi without occlusion were present in group I; none
were present in group II.
Histologic and immunologic analysis. Before
aortic graft implantation, staining with factor VIII
antibody revealed better-preserved endothelium
cells in cryopreserved group I (Fig 2), whereas these
cells were lost in refrigerated group II (Fig 3). 
After 4 weeks of implantation in infected sites,
the histologic findings were correlated with the bac-
terial analysis: aortic wall infected allografts had a
high degree of polynuclear infiltrates (Fig 4).
Endothelial recovery was qualitatively more impor-
tant in group I (cryopreserved) than in group II
(refrigerated). Numerous young plump cells were
only observed in group I (Fig 5).
DISCUSSION
This experimental study suggests the bacterial
resistance superiority of cryopreserved allografts in
an arterial infected dog model. In our results, we
observed the sensitivity of the refrigerated allografts
and the resistance of the cryopreserved allografts to
a specific infection model. 
Cryopreservation is known to retain viability of
endothelial and adventitial cells23; this could
explain the better bacterial resistance. Cold stor-
age leads to progressive morphological and func-
tional deterioration in endothelial cells24,25 and
progressive depolarization of the smooth muscle
cell membrane, which occurs within a few days.26
In cryopreserved allografts, postthaw arterial
smooth function was better preserved when tissues
Fig 5. Histologic aspect of a cryopreserved allograft after 4 weeks of implantation in infected
sites. Factor VIII staining at original magnification of · 100 reveals endothelial cell recovery,
with numerous plump cells (arrows).
were frozen within 10 minutes of being placed in
the cryomedium.27
The role of preservation techniques have previ-
ously been demonstrated. The first experimental
studies of Harrison21 and Foster et al17 reported the
insufficient bacterial resistance of freeze-dried arter-
ial allografts with numerous ruptures. However,
Moore et al,18 in 1974, obtained good bacterial
resistance with fresh arterial allografts implanted in
vivo. They concluded that these allografts were suit-
able material for arterial reconstruction in infected
sites. Our findings also demonstrate that the
improvement of conservation techniques increased
bacterial resistance of the arterial wall.
In our experiment, different antibiotics have
been used in the two-culture medium. The standard
time-kill curve on the same strain of S aureus
showed an intensive and similar bactericidal activity
for the two-preservation medium. These different
antibiotic regimens did not influence the results of
bacterial resistance.
The passive release by the graft of preservation-
medium antibiotics or other antibacterial substances
can be evoked to explain such bacterial resistance.
However, in our virulent model of infection, S
aureus was present up to the time of graft recovery,
and preservation-medium antibiotic activity after 4
weeks of implantation would not explain this differ-
ence. The role of the cellular graft component and
the immune cells of the recipient are currently
unknown. Further investigation may be required to
clarify the relationship of these factors in each
hypothesis.
This infection model is very virulent. No adjunct
antibiotic therapy was given to the animals before or
after implantation, and infected pieces of knitted
Dacron were left in contact with the allografts for a
4-week period, simulating a continued infection
similar to that observed in the graft-enteric fistula.
In contrast, Koskas et al19 observed no bacterial
contamination of refrigerated aortic xenografts used
for the treatment of a less virulent arterial infected
model in dogs. 
We also observed significant thrombogenicity in
cryopreserved grafts, as was previously reported with
cryopreserved vein11,28,29 and arterial allografts.30
Cryopreservation is known to retain endothelial cell
viability.23 However, preservation at 4°C for as long
as 1 week induces a loss of endothelial cells.31 This
factor was also observed in our series. Preservation
of endothelial cells should enhance resistance to
platelet-initiated thrombosis. These endothelial cells
are elicit sites for antigenic expression in an allograft
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environment.32 Five days after implantation, an
intensive reject reaction against arterial allograft
endothelium occurred. Total endothelial destruction
was observed at 11 to 28 days after transplanta-
tion.33 Intimal cell loss was covered by a complete
host tissue resurfacing after 4 months.34 In our
experience, histologic analysis and staining with fac-
tor VIII showed a better recolonization, with young
plump cells in cryopreserved allografts. These plump
cells indicate an important recolonization activity,
which occurred at an earlier stage in group I than in
group II.
In our experiments, only one rupture occurred
in group II, and no rupture occurred in group I,
whereas several clinical series have reported rupture
and cracks in cryopreserved arterial allografts.14-16
The cryopreservation and thawing techniques could
be responsible for arterial wall failures, ie, those
observed with the freeze-dried allografts in the
1950s.17,21,35
In our experience, the only bacterial strain used
was S aureus. Results could be different in the pres-
ence of other highly virulent organisms, such as
Pseudomonas aeruginosa or Candida albicans. Vogt
et al,12 who used cryopreserved arterial allografts,
did not observe any rupture in 19 thoracic or
abdominal aortic highly virulent infected patients.
The antibiotic sensitivities of the two preservation
solutions in our experiment have not yet been test-
ed for other virulent organisms, but could be opti-
mized for different organism strains.
Although further investigation will be required
to determine the bacterial resistance mechanisms,
our study suggests that cryopreserved allografts
could be a useful method in the surgical treatment
of infected vascular prostheses. 
We thank Prof Guy Bonmarchand for welcoming us in
his laboratory, Richard Medeiros for his advice in editing
the manuscript, and Pascal Pommier for his technical assis-
tance in allograft cryopreservation.
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